Haapaniemi Lab

Our focus

Our group focuses on developing targeted therapies for rare immunological conditions, such as primary immunodeficiency diseases and immunological conditions of unknown origin.

Our aim

We aim to optimize the CRISPR-Cas gene editing technology as a gene therapy in these diseases, and stratify the existing therapies – such as biologic drugs and small molecule inhibitors – to better target the underlying molecular pathways that malfunction in individual patients.

Our methods

We utilize custom genomics methods and high-throughput screening to understand immune diseases and optimize CRISPR-Cas9 genome editing towards safe and efficient use in patients. We work with cell models and patient material, and strive to create teams with diverse expertise in molecular and computational biology and clinical medicine.

Our team

Our international team is based at the Centre for Molecular Medicine Norway in Oslo, Norway. We have diverse backgrounds in biosciences and clinical medicine, and have previously worked in academic laboratories, hospitals and private companies.

Find out more!

Our research

Our main projects involve optimizing genome editing, along with personalized use of targeted therapies in rare diseases.

Learn more

Publications

See our latest studies in genome editing and novel genetic etiologies of immunological diseases.

Check them out here

Who supports us?

Instrumentarium Science Foundation